OmniGuide Holdings Announces Successful Completion of Patient Study for iSTONE™ Lithotripsy Technology

BILLERICA, MA / ACCESSWIRE / July 26, 2024 / OmniGuide Holdings, Inc. (OGH) has announced the successful completion of a groundbreaking patient study for its iSTONE™ software. This laser-guided system is designed for real-time automatic target identification in endoscopic stone lithotripsy. This represents a significant milestone in urolithiasis treatment, promising precision and safety in kidney stone management.

In August 2022, the German Federal Ministry of Education and Research awarded LISA Laser Products GmbH, a subsidiary of OmniGuide Holdings, a grant to develop the iSTONE system further. The technology has shown a significant reduction in energy required during lithotripsy procedures in a porcine model, minimizing heat load and potential kidney temperature increase.

The study's results indicate a potential for over 50% reduction in energy applied and reduced risk of kidney damage compared to the traditional Gold Standard Holmium Therapy. "Our approach underscores our patient-focused mission," said Tullio Cappelletto, Global Director of Marketing and Sales.

The OmniGuide Digital Innovation Institute continues to advance medical technology. "Their commitment to patient care has led to the creation of iSTONE," said Robert Allen, CFO of OmniGuide Holdings. The findings will be unveiled in the forthcoming months, positioning OmniGuide Holdings at the forefront of medical innovation.